Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434890 | 0.91 | GRIK1 (0.45) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL19066457 | 0.84 | CSNK2A1 (0.57) | DYRK1ACSNK2A1PARP1CSNK2A2CSNK2B | |
| SCHEMBL30052511 | 0.84 | CSNK2A1 (0.57) | DYRK1ACSNK2A1PARP1CSNK2A2CSNK2B | |
| SCHEMBL3307100 | 0.84 | ROCK2 (0.56) | CSF1RKDREGFR | |
| SCHEMBL3310660 | 0.84 | ROCK2 (0.56) | CSF1RKDREGFR | |
| SCHEMBL4442828 | 0.82 | TNKS2 (0.43) | TNKS2PARP1MAPK14KITEGFR | |
| SCHEMBL2355475 | 0.82 | RAB9A (0.46) | DYRK1ACSNK2A1MAPK14CSNK2A2CSNK2B | |
| SCHEMBL2304728 | 0.82 | DDR2 (0.50) | MAPK14LCKKDR | |
| SCHEMBL4434893 | 0.81 | DYRK1A (0.36) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2304320 | 0.80 | DDR2 (0.53) | MAPK14LCKKDRKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2121692-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008079965-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | GRIK1 1505/4885GRIA1 1997/4885GRIA2 2159/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | GRIK1 1273/4885GRIA1 1760/4885GRIA2 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.